## SEC Form 4

Instruction 1(b).

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

		2. Issuer Name <b>and</b> Ticker or Trading Symbol Repare Therapeutics Inc. [ RPTX ]		tionship of Reporting P all applicable)	erson(s) to Issuer	
Foley Todd				X	Director	10% Owner
				-	Officer (give title	Other (specify
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/18/2021		below)	below)
C/O MPM C	CAPITAL		03/10/2021			
450 KENDA	ALL STREET			_		
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	vidual or Joint/Group Fil	ing (Check Applicable
(Street)				X	Form filed by One Re	eporting Person
CAMBRIDO	GE MA	02142			Form filed by More th Person	an One Reporting
(City)	(State)	(Zip)				

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Shares	05/18/2021		S <sup>(1)</sup>		<b>6,509</b> <sup>(2)</sup>	D	\$33.9 <sup>(3)</sup>	2,596,580	Ι	See Footnote <sup>(4)</sup>
Common Shares	05/18/2021		S <sup>(1)</sup>		3,763 <sup>(5)</sup>	D	\$34.61 <sup>(6)</sup>	2,592,817	Ι	See Footnote <sup>(7)</sup>
Common Shares	05/18/2021		S <sup>(1)</sup>		40 <sup>(8)</sup>	D	\$35.14	2,592,777	Ι	See Footnote <sup>(9)</sup>
Common Shares	05/18/2021		J <sup>(1)(10)</sup>		21,834	D	<b>\$0.00</b> <sup>(10)</sup>	2,570,943	Ι	See Footnote <sup>(11)</sup>
Common Shares	05/19/2021		S <sup>(1)</sup>		4,029(12)	D	\$34.23(13)	2,566,914	I	See Footnote <sup>(14)</sup>
Common Shares	05/19/2021		S <sup>(1)</sup>		1,939(15)	D	<b>\$</b> 35 <sup>(16)</sup>	2,564,975	Ι	See Footnote <sup>(17)</sup>
Common Shares	05/20/2021		S <sup>(1)</sup>		4,122 <sup>(18)</sup>	D	\$34.66 <sup>(19)</sup>	2,560,853	Ι	See Footnote <sup>(20)</sup>
Common Shares	05/20/2021		S <sup>(1)</sup>		265(21)	D	\$35.19(22)	2,560,588	Ι	See Footnote <sup>(23)</sup>

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

#### Explanation of Responses:

1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021.

2. The shares were sold as follows: 6,292 by MPM BioVentures 2014, L.P. ("BV 2014") and 217 by MPM Asset Management Investors BV2014 LLC ("AM BV2014").

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.06 to \$34.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The shares are held as follows: 2,357,748 by BV 2014, 157,677 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 81,155 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The

BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

5. The shares were sold as follows: 3,638 by BV 2014 and 125 by AM BV2014.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$34.07 to \$35.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The shares are held as follows: 2,354,110 by BV 2014, 157,677 by BV 2014(B) and 81,030 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

8. The shares were sold as follows: 39 by BV 2014 and 1 by AM BV2014.

9. The shares are held as follows: 2,354,071 by BV 2014, 157,677 by BV 2014(B) and 81,029 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent

of his pecuniary interest therein.

10. Represents a pro rata in-kind distribution from BV 2014(B) to its limited partners for no consideration.

11. The shares are held as follows: 2,354,071 by BV 2014, 135,843 by BV 2014(B) and 81,029 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

12. The shares were sold as follows: 3,895 by BV 2014 and 134 by AM BV2014.

13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.70 to \$34.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

14. The shares are held as follows: 2,350,176 by BV 2014, 135,843 by BV 2014(B) and 80,895 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

15. The shares were sold as follows: 1,874 by BV 2014 and 65 by AM BV2014.

16. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$34.74 to \$35.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

17. The shares are held as follows: 2,348,302 by BV 2014, 135,843 by BV 2014(B) and 80,830 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

18. The shares were sold as follows: 3,985 by BV 2014 and 137 by AM BV2014.

19. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$34.10 to \$35.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

20. The shares are held as follows: 2,344,317 by BV 2014, 135,843 by BV 2014(B) and 80,693 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

21. The shares were sold as follows: 256 by BV 2014 and 9 by AM BV2014.

22. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.14 to \$35.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

23. The shares are held as follows: 2,344,061 by BV 2014, 135,843 by BV 2014(B) and 80,684 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

### Remarks:

<u>/s/ Todd Foley</u>

05/20/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.